Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, Feb. 21 '26)

Image
By G.M.

 


    Antiviral Res

  1. LIU Q, Tang B, Xuan X, Wang H, et al
    The potential of leritrelvir repositioning for the treatment of coxsackievirus B4 and common enterovirus infections.
    Antiviral Res. 2026 Feb 16:106367. doi: 10.1016/j.antiviral.2026.106367.
    PubMed         Abstract available


    Emerg Infect Dis

  2. KASAI M, Sakuma H, Suzuki M, Nishiyama M, et al
    Life-Threatening SARS-CoV-2-Associated Encephalopathy and Multiorgan Failure in Children, Asia and Oceania, 2022-2024.
    Emerg Infect Dis. 2026;32:169-179.
    PubMed         Abstract available


    Int J Infect Dis

  3. MA Q, Yao L, Ding H, Tian W, et al
    SARS-CoV-2 Variant Specific Protective Immunity and Long-term Immune Recovery in People Living With HIV: A Retrospective Cohort Study.
    Int J Infect Dis. 2026 Feb 16:108491. doi: 10.1016/j.ijid.2026.108491.
    PubMed         Abstract available


    J Med Virol


  4. EXPRESSION OF CONCERN: Resistance-Associated Mutations to the Anti-SARS-CoV-2 Agent Nirmatrelvir: Selection Not Induction.
    J Med Virol. 2026;98:e70841.
    PubMed        


  5. EXPRESSION OF CONCERN: Culture and Identification of a "Deltamicron" SARS-CoV-2 in a Three Cases Cluster in Southern France.
    J Med Virol. 2026;98:e70843.
    PubMed        


    J Virol

  6. ZHOU S, Zhao H, Zhu J, Zhou Y, et al
    Porcine epidemic diarrhea virus manipulates IMPDH-dependent nucleotide biosynthesis to facilitate replication.
    J Virol. 2026;100:e0173625.
    PubMed         Abstract available

  7. WANG J, Zeng Y, Liu Y, Sun H, et al
    ALDH1L1 suppresses the replication of porcine epidemic diarrhea virus by degrading viral nucleocapsid and envelope proteins.
    J Virol. 2026;100:e0193325.
    PubMed         Abstract available


    Lancet Infect Dis

  8. KUPPALLI K
    I worked at WHO: the USA leaving will not make America healthier.
    Lancet Infect Dis. 2026 Feb 13:S1473-3099(26)00069.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  9. SILK BJ, Prill MM, Winn AK, Patton ME, et al
    Respiratory Virus Activity - United States, July 1, 2024-June 30, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:77-84.
    PubMed         Abstract available

  10. RAYKIN J, Rochin I, Wiegand R, Soto V, et al
    COVID-19 Antiviral Prescription Receipt Among Outpatients Aged >/=65 Years - United States, June 1, 2023-September 30, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:69-76.
    PubMed         Abstract available


    Nature

  11. SCHMIDT A, Alawathurage TM, David FS, Ogawa Y, et al
    Host control of persistent Epstein-Barr virus infection.
    Nature. 2026 Feb 19. doi: 10.1038/s41586-026-10274.
    PubMed         Abstract available


    Science

  12. ZHANG H, Floyd K, Fang Z, Hoffmann FA, et al
    Mucosal vaccination in mice provides protection from diverse respiratory threats.
    Science. 2026 Feb 19:eaea1260. doi: 10.1126/science.aea1260.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »